Connecting the Past and Present: An Updated Literature Review of Aquagenic Syringeal Acrokeratoderma.

Aquagenic syringeal acrokeradermatoma (ASA) is a dermatological condition characterized by the transient appearance of edematous, white, translucent papules on the palms, typically triggered by water exposure. While ASA is most commonly associated with cystic fibrosis (CF) and predominantly affects young females, there has been a significant increase in ASA cases since the most recent update in 2015. The COVID-19 pandemic increased the number of patients diagnosed with ASA following exposure to the viral infection.

Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.

Introduction: In the OPTIMISMM trial, pomalidomide/bortezomib/dexamethasone (PVd) significantly prolonged median progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) in lenalidomide-exposed relapsed and refractory multiple myeloma (RRMM). We report final overall survival (OS) and updated efficacy analyses.

Methods: Adults with RRMM who had 1-3 prior regimens, including lenalidomide (≥ 2 cycles), were assigned (1:1) to PVd or Vd.

A Case of Aquagenic Syringeal Acrokeratoderma in a Male Patient Undergoing Treatment With an Angiotensin-Converting Enzyme Inhibitor.

Aquagenic syringeal acrokeratoderma (ASA) is a rare dermatological condition characterized by the transient appearance of edematous, white, translucent papules on the palms following water exposure. While the condition is most commonly associated with cystic fibrosis (CF) and predominantly affects young women, this report presents a unique case in a 24-year-old man without a history of cystic fibrosis. The patient reported a 10-month history of painful, pruritic eruptions on the hands following exposure to water.